Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCP-020 Photoallergy Study in Healthy Volunteers
NCT03473197Phase 1Completed
- Sponsor
- Castle Creek Biosciences
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AC-203 in epidermolysis bullosa simplex (EBS), sponsored by Castle Creek Biosciences. Primary endpoint: Observed Photoallergy (Photosensitization): Number of Skin Sites by Maximum Total Irritation Score at 72 hours. Started Jan 2018; status: completed.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT03473197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473197.